Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
2.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
3.

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.

Lyseng-Williamson KA.

Mol Diagn Ther. 2012 Oct;16(5):317-22. doi: 10.1007/s40291-012-0007-2. Review.

PMID:
23055389
4.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
5.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208. Review.

6.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
7.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

8.

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Chen J, Ye Y, Sun H, Shi G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72. doi: 10.1007/s00280-012-2005-9. Epub 2012 Oct 23. Review.

PMID:
23090619
9.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
10.

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL.

Cancer. 2013 Feb 15;119(4):714-21. doi: 10.1002/cncr.27804. Epub 2012 Sep 12. Review.

11.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
12.

Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.

Wang L, Chen X, Li W, Sheng Z.

Anticancer Drugs. 2012 Feb;23(2):155-60. doi: 10.1097/CAD.0b013e32834c3256. Review.

PMID:
21955998
13.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

14.

Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM.

World J Gastroenterol. 2014 Apr 21;20(15):4263-75. doi: 10.3748/wjg.v20.i15.4263. Review.

15.

The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.

Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F.

Oncology. 2009;77 Suppl 1:57-68. doi: 10.1159/000258497. Epub 2010 Feb 2. Review.

PMID:
20130433
16.

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

Stintzing S, Heinemann V, Moosmann N, Hiddemann W, Jung A, Kirchner T.

Dtsch Arztebl Int. 2009 Mar;106(12):202-6. doi: 10.3238/arztebl.2009.0202. Epub 2009 Mar 20. Review.

17.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

18.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

19.

KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.

Baynes RD, Gansert J.

Am J Ther. 2009 Nov-Dec;16(6):554-61. doi: 10.1097/MJT.0b013e318199fa17. Review.

PMID:
19352138
20.

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F.

Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. doi: 10.1038/nrclinonc.2009.111. Epub 2009 Jul 28. Review.

PMID:
19636327
Items per page

Supplemental Content

Write to the Help Desk